A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL).

Trial Profile

A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL).

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Hodgkin's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 18 Jul 2016 Final Results published in the Blood (2016).
    • 18 Jul 2016 According to a Seattle Genetics media release, final results from this study were published in the journal Blood.
    • 18 Jul 2016 Final data from the study published in the Seattle Genetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top